Nucala (mepolizumab) is now available by prescription in the United States, according to manufacturer GlaxoSmithKline. The product is the first and only biologic add-on therapy for people 12 years and older with severe asthma with an eosinophilic phenotype, according to GSK.

The therapy is administered by a healthcare professional as a 100mg fixed dose subcutaneous injection every 28 days. The product is not indicated for the treatment of other eosinophilic conditions or relief of acute bronchospasm or status asthmaticus.

The FDA approved the drug in early November.

GSK is also launching a complimentary patient support hotline, Gateway to Nucala, designed to provide personalized assistance. This program can be accessed at 844-4-NUCALA (844-468-2252). Program representatives are available from 8 AM to 8 PM ET, Monday through Friday.

“The goal of Gateway to Nucala is to support patients for who Nucala is appropriate with just one phone number where they can call and get answers to their questions about insurance coverage and access to treatment, and help alleviate any uncertainty in that regard. I encourage patients to call and enroll in the program,” said Anjana Narain, Vice President, Respiratory Biologics Specialty, GSK.

For full US prescribing information, please click here.